 --Of the 15 patients evaluable for efficacy, 7 47 had mCR and 5 33 had SD for a total disease control rate of 80-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHANGHAI and HONG KONG, June 8, 2021 PRNewswire -- Antengenes Partner, Karyopharm Therapeutics Inc. Nasdaq: KPTI, announced updated data of eltanexor for the treatment of patients with hypomethylating agent HMA refractory myelodysplastic syndrome MDS at the 2021 American Society of Clinical Oncology ASCO Annual Meeting. This Phase III study evaluated single-agent eltanexor in patients with higher-risk MDS, ie, high-risk or intermediate-2 MDS by the International Prognostic Scoring System IPSS and 5-19 myeloblasts. 